TPMT and acute lymphoblastic leukemia: By analogy, TPMT genotyping is an example of how pharmacogenetic profiling can add to the individualization of therapy compared with toxicity-based guidelines, since for childhood ALL patients with TPMT low activity, the cure rate seems independent of the degree of myelosuppression obtained, whereas for TPMT high-activity patients 6MP/MTX dose adjustment during maintenance therapy to obtain myelosuppression seems to improve the cure rate [11].